Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May 29;22(1):299.
doi: 10.1186/s12964-024-01580-3.

Ephs in cancer progression: complexity and context-dependent nature in signaling, angiogenesis and immunity

Xiaoting Guo  1   2   3 , Yanyi Yang  4 , Jingqun Tang  5   6 , Juanjuan Xiang  7   8   9
Affiliations
Review

Ephs in cancer progression: complexity and context-dependent nature in signaling, angiogenesis and immunity

Xiaoting Guo et al. Cell Commun Signal. .

Abstract

Eph receptors constitute the largest family of receptor tyrosine kinases, comprising 14 distinct members classified into two subgroups: EphAs and EphBs.. Despite their essential functions in normal physiological processes, accumulating evidence suggests that the involvement of the Eph family in cancer is characterized by a dual and often contradictory nature. Research indicates that Eph/ephrin bidirectional signaling influences cell-cell communication, subsequently regulating cell migration, adhesion, differentiation and proliferation. The contradictory functionalities may arise from the diversity of Eph signaling pathways and the heterogeneity of different cancer microenvironment. In this review, we aim to discuss the dual role of the Eph receptors in tumor development, attempting to elucidate the paradoxical functionality through an exploration of Eph receptor signaling pathways, angiogenesis, immune responses, and more. Our objective is to provide a comprehensive understanding of the molecular mechanisms underlying tumor development. Additionally, we will explore the evolving landscape of utilizing Eph receptors as potential targets for tumor therapy and diagnostic tools.

Keywords: Eph/ephrin; Immune; Pain; Tumor; Vascular.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
The Hazard Ratio of survival events associated with Eph receptor expressions across different cancer types. The TISCH2 database (http://tisch.compgenomics.org/), containing scRNA-seq data from more than 50 cancer types, was utilized to analyze the association of Eph receptor expression and HR of survival. An HR > 1 indicates a high risk of death, while an HR < 1 indicates a low risk of death. A HR of patient survival according to the expression of EphA2 in distinct cancer types from datasets. B HR of patient survival according to the expression of EphB1 in distinct cancer types from datasets. C HR of patient survival according to the expression of EphB4 in distinct cancer types from datasets
Fig. 2
Fig. 2
The molecular structure of Ephrin-Eph and signaling pathway. A The molecular structures of ephrinA and ephrinB are different, while their receptors are similar. B, C The EphA and EphB receptor can bind to the ligands present on the same cell with the receptor, known as cis signaling, activating downstream signals. D, E The EphA and EphB receptor can bind to ligands located on neighboring cells, referred to as trans signaling, activating downstream signals. F Ephrin-Eph signaling engages in crosstalk with other RTKs such as EGFR and GFR, involving ERK, Ras and other downstream molecules
Fig. 3
Fig. 3
Working models of Eph receptors and their ligands in physiological functions. A Ephrin-Eph signaling contains reverse signal and forward signal, leading to the phosphorylation of downstream molecules. The forward signal influences the expression of additional downstream molecules, thereby impacting processes such as angiogenesis, cell proliferation, cell adhesion, and migration. B Ephrin-Eph signaling engages in cross talk with other RTKs, such as VEGFR, exerting regulatory effects that can either suppress or promote tumor development
Fig. 4
Fig. 4
The expression of EphB1 in various cell types. The expression of EphB1 in various cell types was analyzed in publicly accessible single-cell RNA-seq (scRNA seq) dataset of colorectal cancer tissues (EMTAB8107). A UMAP plot with cell type annotations displayed at the top of the tab. B UMAP plot shows the expression level of EphB1 in different cell types. C Pie plot shows the cell number distribution of each cell type. D Violin plot reflects the distribution of EphB1 gene expression in various cell types
Fig. 5
Fig. 5
Average expression of Eph receptors. The TISCH2 database (http://tisch.compgenomics.org/), containing scRNA-seq data from more than 50 cancer types, was utilized to analyze the expression of Eph receptors. A The expression of EphA2 across datasets in different cell types. B The expression of EphB1 across datasets in different cell types. C The expression of EphB4 across datasets in different cell types
Fig. 6
Fig. 6
Therapeutic strategies targeting Eph receptors. These strategies can inhibit tumor progression through various approaches and also impact pain behaviors
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Gucciardo E, Sugiyama N, Lehti K. Eph- and ephrin-dependent mechanisms in tumor and stem cell dynamics. Cell Mol Life Sci. 2014;71:3685–3710. doi: 10.1007/s00018-014-1633-0. - DOI - PMC - PubMed
    1. Unified nomenclature for Eph family receptors and their ligands, the ephrins Eph Nomenclature Committee. Cell. 1997;90:403–404. doi: 10.1016/s0092-8674(00)80500-0. - DOI - PubMed
    1. Nakada M, Hayashi Y, Hamada J. Role of Eph/ephrin tyrosine kinase in malignant glioma. Neuro Oncol. 2011;13:1163–1170. doi: 10.1093/neuonc/nor102. - DOI - PMC - PubMed
    1. Lisabeth EM, Falivelli G, Pasquale EB. Eph receptor signaling and ephrins. Cold Spring Harb Perspect Biol. 2013;5. 10.1101/cshperspect.a009159. - PMC - PubMed
    1. Brantley-Sieders DM, Zhuang G, Hicks D, Fang WB, Hwang Y, Cates JM, Coffman K, Jackson D, Bruckheimer E, Muraoka-Cook RS, Chen J. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest. 2008;118:64–78. doi: 10.1172/JCI33154. - DOI - PMC - PubMed

Substances

LinkOut - more resources